These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 14701778)

  • 1. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
    Meyers CA; Smith JA; Bezjak A; Mehta MP; Liebmann J; Illidge T; Kunkler I; Caudrelier JM; Eisenberg PD; Meerwaldt J; Siemers R; Carrie C; Gaspar LE; Curran W; Phan SC; Miller RA; Renschler MF
    J Clin Oncol; 2004 Jan; 22(1):157-65. PubMed ID: 14701778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
    Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
    J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
    Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.
    Mehta MP; Shapiro WR; Glantz MJ; Patchell RA; Weitzner MA; Meyers CA; Schultz CJ; Roa WH; Leibenhaut M; Ford J; Curran W; Phan S; Smith JA; Miller RA; Renschler MF
    J Clin Oncol; 2002 Aug; 20(16):3445-53. PubMed ID: 12177105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118.
    Corn BW; Moughan J; Knisely JP; Fox SW; Chakravarti A; Yung WK; Curran WJ; Robins HI; Brachman DG; Henderson RH; Mehta MP; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):71-8. PubMed ID: 18164829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
    Chang EL; Wefel JS; Hess KR; Allen PK; Lang FF; Kornguth DG; Arbuckle RB; Swint JM; Shiu AS; Maor MH; Meyers CA
    Lancet Oncol; 2009 Nov; 10(11):1037-44. PubMed ID: 19801201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function.
    Li J; Bentzen SM; Renschler M; Mehta MP
    J Clin Oncol; 2007 Apr; 25(10):1260-6. PubMed ID: 17401015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis.
    Li J; Bentzen SM; Li J; Renschler M; Mehta MP
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):64-70. PubMed ID: 18406884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.
    McHaffie DR; Chabot P; Dagnault A; Suh JH; Fortin MA; Chang E; Timmerman R; Souhami L; Grecula J; Nabid A; Schultz C; Werner-Wasik M; Gaspar LE; Brachman D; Mody T; Mehta MP
    J Neurooncol; 2011 Nov; 105(2):301-8. PubMed ID: 21523486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
    Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motexafin gadolinium in the treatment of brain metastases.
    Richards GM; Mehta MP
    Expert Opin Pharmacother; 2007 Feb; 8(3):351-9. PubMed ID: 17266469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
    Carde P; Timmerman R; Mehta MP; Koprowski CD; Ford J; Tishler RB; Miles D; Miller RA; Renschler MF
    J Clin Oncol; 2001 Apr; 19(7):2074-83. PubMed ID: 11283141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study.
    Chabot P; Hsia TC; Ryu JS; Gorbunova V; Belda-Iniesta C; Ball D; Kio E; Mehta M; Papp K; Qin Q; Qian J; Holen KD; Giranda V; Suh JH
    J Neurooncol; 2017 Jan; 131(1):105-115. PubMed ID: 27655223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study.
    Tsai PF; Yang CC; Chuang CC; Huang TY; Wu YM; Pai PC; Tseng CK; Wu TH; Shen YL; Lin SY
    Radiat Oncol; 2015 Dec; 10():253. PubMed ID: 26654128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Postmus PE; Haaxma-Reiche H; Smit EF; Groen HJ; Karnicka H; Lewinski T; van Meerbeeck J; Clerico M; Gregor A; Curran D; Sahmoud T; Kirkpatrick A; Giaccone G
    J Clin Oncol; 2000 Oct; 18(19):3400-8. PubMed ID: 11013281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
    Knisely JP; Berkey B; Chakravarti A; Yung AW; Curran WJ; Robins HI; Movsas B; Brachman DG; Henderson RH; Mehta MP
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):79-86. PubMed ID: 18164847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.
    Evens AM
    Curr Opin Oncol; 2004 Nov; 16(6):576-80. PubMed ID: 15627019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for preservation of memory function in patients with brain metastases.
    Dye NB; Gondi V; Mehta MP
    Chin Clin Oncol; 2015 Jun; 4(2):24. PubMed ID: 26112810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported cognitive outcomes in patients with brain metastases before and after radiation therapy.
    Cole AM; Scherwath A; Ernst G; Lanfermann H; Bremer M; Steinmann D
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):705-12. PubMed ID: 24064320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the impact of hippocampal sparing during whole brain radiotherapy on neurocognitive functions: A preliminary report of a prospective phase II study.
    Lin SY; Yang CC; Wu YM; Tseng CK; Wei KC; Chu YC; Hsieh HY; Wu TH; Pai PC; Hsu PW; Chuang CC
    Biomed J; 2015; 38(5):439-49. PubMed ID: 25994802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.